Sign in

CIK 0001651308 · Large accelerated filer

BeOne Medicines Ltd.

Sign in to watch
Ticker
BEIGF
Exchange
Nasdaq, OTC
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
operating
EIN
981209416
Phone
41-616851900
Business address
C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
Former names
BeiGene, Ltd.

Securities

  • ONC American Depositary Shares Nasdaq
  • BEIGF Common stock OTC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$48,487,541
in 9 filings, $47.8M under 10b5-1 plans

Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Wang Xiaodong −$46.8M Director sold 100% of stake
  2. Lee Chan Henry −$865K SVP, General Counsel sold 100% of stake
  3. Ball Titus B. −$679K Principal Accounting Officer sold 100% of stake
  4. Wu Xiaobin −$106K President and COO sold 100% of stake

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-04-08 Lee Chan Henry SVP, General Counsel Option exercise · Share Option (Right to Buy) 10b5-1 −1,313 21,177
2026-04-08 Lee Chan Henry SVP, General Counsel Option exercise · Share Option (Right to Buy) 10b5-1 −1,729 84,955
2026-04-08 Lee Chan Henry SVP, General Counsel Option exercise · Share Option (Right to Buy) 10b5-1 −1,274 109,122
2026-03-11 Lee Chan Henry SVP, General Counsel Option exercise 10b5-1 +110 $194.47 $21K 110
2026-03-11 Lee Chan Henry SVP, General Counsel Option exercise 10b5-1 +133 $213.32 $28K 243
2026-03-11 Lee Chan Henry SVP, General Counsel Option exercise 10b5-1 +98 $159.03 $16K 341
2026-03-11 Lee Chan Henry SVP, General Counsel Sale 10b5-1 −341 $300.00 $102K 0
2026-03-11 Lee Chan Henry SVP, General Counsel Option exercise · Share Option (Right to Buy) 10b5-1 −1,430 22,490
2026-03-11 Lee Chan Henry SVP, General Counsel Option exercise · Share Option (Right to Buy) 10b5-1 −1,729 86,684
2026-03-11 Lee Chan Henry SVP, General Counsel Option exercise · Share Option (Right to Buy) 10b5-1 −1,274 110,396
2026-03-06 Rosenberg Aaron Chief Financial Officer Grant or award +79,014 294,346
2026-03-06 Rosenberg Aaron Chief Financial Officer Grant or award +40,573 334,919
2026-03-06 Lee Chan Henry SVP, General Counsel Grant or award +65,390 288,496
2026-03-06 Lee Chan Henry SVP, General Counsel Grant or award +29,874 318,370
2026-03-06 Wang Lai President, Global Head of R&D Grant or award +112,606 1,564,030
2026-03-06 Wang Lai President, Global Head of R&D Grant or award +55,029 1,619,059
2026-03-06 Wu Xiaobin President and COO Grant or award +168,922 1,137,900
2026-03-06 Wu Xiaobin President and COO Grant or award +78,624 1,216,524
2026-03-06 OYLER JOHN Chief Executive Officer Grant or award +326,976 5,491,339
2026-03-06 OYLER JOHN Chief Executive Officer Grant or award +117,936 5,609,275

Page 14 of 71 · 1,406 trades